pimobendan and Canine Diseases studies

pimobendan and Canine Diseases

pimobendan has been researched along with Canine Diseases in 45 studies

pimobendan: produces arterial & venous dilatation in dogs; structure given in first source

Research Excerpts

Excerpt	Relevance	Reference
"The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively."	9.41	Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021)
"A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan."	9.27	Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. ( Forster, S; Hirakawa, A; King, JN; Otaki, H; Sakakibara, N; Seewald, W; Sonobe, J, 2018)
"Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated."	9.22	Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016)
"To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD)."	9.20	Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015)
"To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)."	9.11	Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005)
"Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure."	8.82	Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004)
"The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)."	7.85	Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017)
"Pimobendan has gained enormous importance in the treatment of mitral valve disease in dogs."	6.90	Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. ( Bach, JP; Iwanuk, N; Nolte, I; Pilgram, A; Raue, J; Rohn, K; Rumstedt, K; Sehn, M; Wall, L, 2019)
"Pimobendan is an inotropic drug with phosphodiesterase 3 inhibitory and calcium-sensitizing effects."	5.56	Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension. ( Kawamoto, S; Miki, S; Morita, T; Nakamura, K; Osuga, T; Sasaoka, K; Takiguchi, M, 2020)
"The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively."	5.41	Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021)
"Triple therapy (TT) consisting of furosemide, pimobendan, and an angiotensin-converting enzyme inhibitor (ACEI) frequently is recommended for the treatment of congestive heart failure (CHF) attributable to myxomatous mitral valve disease (MMVD)."	5.34	Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. ( Bauer, A; Gaugele, J; Glaus, T; Holler, P; Keller, L; Killich, M; Kresken, JG; Küchenhof, H; Simak, J; Wendt, R; Wess, G, 2020)
"A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan."	5.27	Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. ( Forster, S; Hirakawa, A; King, JN; Otaki, H; Sakakibara, N; Seewald, W; Sonobe, J, 2018)
"Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described."	5.27	Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Schummer, C; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2018)
"Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated."	5.22	Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016)
"To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD)."	5.20	Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015)
"To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)."	5.11	Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005)
"Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure."	4.82	Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004)
"For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day."	3.88	Clinical findings and survival time in dogs with advanced heart failure. ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018)
"The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)."	3.85	Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017)
"This retrospective study reports the survival time [onset of congestive heart failure (CHF) to death from any cause] of 21 dogs with mitral regurgitation (MR) and CHF treated with a combination of furosemide, angiotensin-converting enzyme inhibitor (ACEI, benazepril, or enalapril), pimobendan, spironolactone, and amlodipine."	3.77	Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. ( de Madron, E; King, JN; Strehlau, G; White, RV, 2011)
"Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly."	3.01	The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study. ( Bach, JP; Beyerbach, M; Klein, S; Nolte, I; Raue, JF; Rumstedt, K; Sehn, M; Treese, JS; Weiner, F, 2021)
"Pimobendan has gained enormous importance in the treatment of mitral valve disease in dogs."	2.90	Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. ( Bach, JP; Iwanuk, N; Nolte, I; Pilgram, A; Raue, J; Rohn, K; Rumstedt, K; Sehn, M; Wall, L, 2019)
"Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs."	2.46	Current use of pimobendan in canine patients with heart disease. ( Boswood, A, 2010)
"Pimobendan has been proven to delay the onset of congestive heart failure (CHF) in dogs with mitral regurgitation (MR); however, molecular underlying mechanisms have not been fully elucidated."	1.91	Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation. ( Boonpala, P; Ji-Au, W; Kijtawornrat, A; Kumphune, S; Panyasing, Y; Saengklub, N; Srikam, S, 2023)
" Plasma concentrations of pimobendan and O-demethylpimobendan (ODMP) were measured, and pharmacokinetic parameters were calculated for pimobendan by noncompartmental analysis."	1.72	Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus). ( Diao, SM; Gunther-Harrington, CT; Guzman, DS; Hawkins, MG; Knych, HK; Masri, AE; Ozawa, SM, 2022)
"cardiac death or death for other causes)."	1.62	Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols. ( Bagardi, M; Brambilla, PG; Galizzi, A; Locatelli, C; Malchiodi, D; Zanaboni, A, 2021)
" Angiotensin-converting enzyme inhibitor dosage and RAAS inhibition were greater in stage D, compared to stage C dogs."	1.56	Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. ( Adin, D; Atkins, C; Kurtz, K; Papich, MG; Vaden, S, 2020)
"Pimobendan is a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects."	1.56	Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease. ( Bode, EF; Dukes-McEwan, J; Hodgkiss-Geere, HM; Maddox, TW; Neves, J; Sarcinella, F, 2020)
"Pimobendan is an inotropic drug with phosphodiesterase 3 inhibitory and calcium-sensitizing effects."	1.56	Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension. ( Kawamoto, S; Miki, S; Morita, T; Nakamura, K; Osuga, T; Sasaoka, K; Takiguchi, M, 2020)
"Primary adrenocortical carcinomas developed in the dog met the definition of bilateral incidental adrenal gland masses (IAGMs)."	1.46	Clinical and pathological features and outcome of bilateral incidental adrenocortical carcinomas in a dog. ( Hasegawa, A; Itoh, H; Kishimoto, M; Murayama, H; Nabeta, R; Ogawa, M; Ohmori, K; Osada, H; Shibutani, M; Yoshida, T, 2017)
"In dogs with canine monocytic ehrlichiosis (CME), respiratory signs are uncommon and clinical and radiographic signs of interstitial pneumonia are poorly described."	1.43	Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog. ( Broens, EM; Dobak, TP; Toom, ML; Valtolina, C, 2016)
"Pimobendan has a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting PDEIII."	1.34	Effects of pimobendan for mitral valve regurgitation in dogs. ( Hara, A; Kanno, N; Kano, R; Kawasaki, M; Kuse, H; Sasaki, Y, 2007)

Research

Studies (45)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (20.00)	29.6817
2010's	22 (48.89)	24.3611
2020's	14 (31.11)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

9 (20.00)

29.6817

2010's

22 (48.89)

24.3611

2020's

14 (31.11)

2.80

Authors

Authors	Studies
Klein, S	1
Nolte, I	3
Rumstedt, K	3
Sehn, M	3
Raue, JF	1
Weiner, F	1
Treese, JS	1
Beyerbach, M	1
Bach, JP	3
Bagardi, M	2
Palermo, V	1
Locatelli, C	2
Colombo, FM	1
Pazzagli, L	1
Brambilla, PG	2
Ozawa, SM	1
Guzman, DS	1
Hawkins, MG	1
Diao, SM	1
Masri, AE	1
Gunther-Harrington, CT	2
Knych, HK	1
Kaplan, JL	2
Visser, LC	2
Ontiveros, ES	1
Wittenburg, LA	1
Palm, CA	1
Stern, JA	1
Ellis-Reis, RE	1
Hsue, W	1
Sharpe, AN	1
Boonpala, P	2
Saengklub, N	2
Srikam, S	1
Ji-Au, W	1
Panyasing, Y	1
Kumphune, S	1
Kijtawornrat, A	2
Pirintr, P	1
Hamlin, RL	1
Iwanuk, N	2
Wall, L	2
Raue, J	2
Pilgram, A	2
Rohn, K	1
Adin, D	1
Kurtz, K	1
Atkins, C	1
Papich, MG	1
Vaden, S	1
Sarcinella, F	1
Neves, J	1
Maddox, TW	1
Hodgkiss-Geere, HM	1
Bode, EF	1
Dukes-McEwan, J	4
Pariaut, R	1
Jung, SW	1
Vila, J	1
Newhard, DK	1
Wess, G	4
Kresken, JG	3
Wendt, R	1
Gaugele, J	1
Killich, M	1
Keller, L	1
Simak, J	1
Holler, P	1
Bauer, A	1
Küchenhof, H	1
Glaus, T	2
Morita, T	1
Nakamura, K	1
Osuga, T	1
Kawamoto, S	1
Miki, S	1
Sasaoka, K	1
Takiguchi, M	1
Schober, KE	1
Rush, JE	2
Luis Fuentes, V	1
Summerfield, NJ	1
Wright, K	1
Lehmkuhl, L	1
Sayer, MP	1
Loureiro, J	1
MacGregor, J	1
Mohren, N	1
Zanaboni, A	1
Galizzi, A	1
Malchiodi, D	1
King, JN	3
Hirakawa, A	2
Sonobe, J	1
Otaki, H	1
Sakakibara, N	1
Seewald, W	1
Forster, S	1
Nabeta, R	1
Osada, H	1
Ogawa, M	1
Hasegawa, A	1
Kishimoto, M	1
Murayama, H	1
Yoshida, T	1
Shibutani, M	1
Itoh, H	1
Ohmori, K	1
Boswood, A	7
Gordon, SG	2
Häggström, J	3
Stepien, RL	3
Oyama, MA	4
Keene, BW	2
Bonagura, J	2
MacDonald, KA	2
Patteson, M	6
Smith, S	6
Fox, PR	2
Sanderson, K	2
Woolley, R	2
Szatmári, V	2
Menaut, P	2
Church, WM	2
O'Sullivan, ML	2
Jaudon, JP	2
Rush, J	2
Barrett, KA	2
Rosenthal, SL	2
Saunders, AB	3
Ljungvall, I	2
Deinert, M	2
Bomassi, E	2
Estrada, AH	2
Fernandez Del Palacio, MJ	2
Moise, NS	3
Abbott, JA	2
Fujii, Y	2
Spier, A	2
Luethy, MW	2
Santilli, RA	2
Uechi, M	3
Tidholm, A	2
Schummer, C	1
Watson, P	2
Beaumier, A	1
Yang, VK	1
Freeman, LM	1
Hezzell, MJ	1
Block, CL	1
Laughlin, DS	1
Hillyer, S	1
Hezzell, M	1
Place, E	1
Tjostheim, SS	1
Kellihan, HB	1
Grint, KA	1
Lake-Bakaar, GA	1
Singh, MK	1
Kass, PH	1
Griffiths, LG	1
Toom, ML	1
Dobak, TP	1
Broens, EM	1
Valtolina, C	1
Apple, SM	1
Menciotti, G	1
Braz-Ruivo, L	1
Crosara, S	1
Borgarelli, M	1
Mizuno, M	1
Yamano, S	1
Chimura, S	1
Takusagawa, Y	1
Sawada, T	1
Maetani, S	1
Takahashi, A	1
Mizuno, T	1
Harada, K	1
Shinoda, A	1
Uchida, S	1
Takeuchi, J	1
Mizukoshi, T	1
Endo, M	1
French, A	3
Little, C	3
Swift, S	3
Willis, R	2
Winter, RL	1
Hariu, CD	1
Martin, MW	1
Stafford Johnson, MJ	1
Strehlau, G	2
Bowles, D	1
Fry, D	1
de Madron, E	1
White, RV	1
Caivano, D	1
Birettoni, F	1
Fruganti, A	1
Rishniw, M	1
Knafelz, P	1
Porciello, F	1
McEwan, JD	1
Butson, R	1
Fuentes, VL	2
Smith, PJ	1
French, AT	1
Van Israël, N	1
Smith, SG	1
Swift, ST	1
Lee, AJ	1
Corcoran, BM	1
Summerfield, N	1
Wotton, P	1
Martin, M	1
Johnson, M	1
Culshaw, G	1
Smith, P	1
Ferasin, L	1
Marcora, S	1
Kanno, N	1
Kuse, H	1
Kawasaki, M	1
Hara, A	1
Kano, R	1
Sasaki, Y	1

Studies

Klein, S

Nolte, I

Rumstedt, K

Sehn, M

Raue, JF

Weiner, F

Treese, JS

Beyerbach, M

Bach, JP

Bagardi, M

Palermo, V

Locatelli, C

Colombo, FM

Pazzagli, L

Brambilla, PG

Ozawa, SM

Guzman, DS

Hawkins, MG

Diao, SM

Masri, AE

Gunther-Harrington, CT

Knych, HK

Kaplan, JL

Visser, LC

Ontiveros, ES

Wittenburg, LA

Palm, CA

Stern, JA

Ellis-Reis, RE

Hsue, W

Sharpe, AN

Boonpala, P

Saengklub, N

Srikam, S

Ji-Au, W

Panyasing, Y

Kumphune, S

Kijtawornrat, A

Pirintr, P

Hamlin, RL

Iwanuk, N

Wall, L

Raue, J

Pilgram, A

Rohn, K

Adin, D

Kurtz, K

Atkins, C

Papich, MG

Vaden, S

Sarcinella, F

Neves, J

Maddox, TW

Hodgkiss-Geere, HM

Bode, EF

Dukes-McEwan, J

Pariaut, R

Jung, SW

Vila, J

Newhard, DK

Wess, G

Kresken, JG

Wendt, R

Gaugele, J

Killich, M

Keller, L

Simak, J

Holler, P

Bauer, A

Küchenhof, H

Glaus, T

Morita, T

Nakamura, K

Osuga, T

Kawamoto, S

Miki, S

Sasaoka, K

Takiguchi, M

Schober, KE

Rush, JE

Luis Fuentes, V

Summerfield, NJ

Wright, K

Lehmkuhl, L

Sayer, MP

Loureiro, J

MacGregor, J

Mohren, N

Zanaboni, A

Galizzi, A

Malchiodi, D

King, JN

Hirakawa, A

Sonobe, J

Otaki, H

Sakakibara, N

Seewald, W

Forster, S

Nabeta, R

Osada, H

Ogawa, M

Hasegawa, A

Kishimoto, M

Murayama, H

Yoshida, T

Shibutani, M

Itoh, H

Ohmori, K

Boswood, A

Gordon, SG

Häggström, J

Stepien, RL

Oyama, MA

Keene, BW

Bonagura, J

MacDonald, KA

Patteson, M

Smith, S

Fox, PR

Sanderson, K

Woolley, R

Szatmári, V

Menaut, P

Church, WM

O'Sullivan, ML

Jaudon, JP

Rush, J

Barrett, KA

Rosenthal, SL

Saunders, AB

Ljungvall, I

Deinert, M

Bomassi, E

Estrada, AH

Fernandez Del Palacio, MJ

Moise, NS

Abbott, JA

Fujii, Y

Spier, A

Luethy, MW

Santilli, RA

Uechi, M

Tidholm, A

Schummer, C

Watson, P

Beaumier, A

Yang, VK

Freeman, LM

Hezzell, MJ

Block, CL

Laughlin, DS

Hillyer, S

Hezzell, M

Place, E

Tjostheim, SS

Kellihan, HB

Grint, KA

Lake-Bakaar, GA

Singh, MK

Kass, PH

Griffiths, LG

Toom, ML

Dobak, TP

Broens, EM

Valtolina, C

Apple, SM

Menciotti, G

Braz-Ruivo, L

Crosara, S

Borgarelli, M

Mizuno, M

Yamano, S

Chimura, S

Takusagawa, Y

Sawada, T

Maetani, S

Takahashi, A

Mizuno, T

Harada, K

Shinoda, A

Uchida, S

Takeuchi, J

Mizukoshi, T

Endo, M

French, A

Little, C

Swift, S

Willis, R

Winter, RL

Hariu, CD

Martin, MW

Stafford Johnson, MJ

Strehlau, G

Bowles, D

Fry, D

de Madron, E

White, RV

Caivano, D

Birettoni, F

Fruganti, A

Rishniw, M

Knafelz, P

Porciello, F

McEwan, JD

Butson, R

Fuentes, VL

Smith, PJ

French, AT

Van Israël, N

Smith, SG

Swift, ST

Lee, AJ

Corcoran, BM

Summerfield, N

Wotton, P

Martin, M

Johnson, M

Culshaw, G

Smith, P

Ferasin, L

Marcora, S

Kanno, N

Kuse, H

Kawasaki, M

Hara, A

Kano, R

Sasaki, Y

Reviews

4 reviews available for pimobendan and Canine Diseases

Article	Year
Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease? The Veterinary record, 2018, Dec-08, Volume: 183, Issue:22 Topics: Animals; Arrhythmias, Cardiac; Dog Diseases; Dogs; Heart Diseases; Pyridazines; Vasodilator Agents	2018
Current use of pimobendan in canine patients with heart disease. The Veterinary clinics of North America. Small animal practice, 2010, Volume: 40, Issue:4 Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Diseases; Ma	2010
Pimobendan and its use in treating canine congestive heart failure. Compendium (Yardley, PA), 2011, Volume: 33, Issue:11 Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Treatment Outcome	2011
Use of pimobendan in the management of heart failure. The Veterinary clinics of North America. Small animal practice, 2004, Volume: 34, Issue:5 Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Heart Failure; Phosphodiesteras	2004

Article

Year

Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?

The Veterinary record, 2018, Dec-08, Volume: 183, Issue:22

Topics: Animals; Arrhythmias, Cardiac; Dog Diseases; Dogs; Heart Diseases; Pyridazines; Vasodilator Agents

2018

Current use of pimobendan in canine patients with heart disease.

The Veterinary clinics of North America. Small animal practice, 2010, Volume: 40, Issue:4

Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Diseases; Ma

2010

Pimobendan and its use in treating canine congestive heart failure.

Compendium (Yardley, PA), 2011, Volume: 33, Issue:11

Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Treatment Outcome

2011

Use of pimobendan in the management of heart failure.

The Veterinary clinics of North America. Small animal practice, 2004, Volume: 34, Issue:5

Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Heart Failure; Phosphodiesteras

2004

Trials

13 trials available for pimobendan and Canine Diseases

Article	Year
The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study. BMC veterinary research, 2021, Sep-25, Volume: 17, Issue:1 Topics: Animals; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Method; Heart Valve Diseases; Pyridazi	2021
Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease. Journal of veterinary internal medicine, 2022, Volume: 36, Issue:6 Topics: Animals; Dog Diseases; Dogs; Heart Valve Diseases; Kidney; Mitral Valve; Prospective Studies; Qualit	2022
Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. PloS one, 2019, Volume: 14, Issue:10 Topics: Animals; Cardiomegaly; Dog Diseases; Dogs; Echocardiography; Exercise Test; Female; Heart Murmurs; H	2019
Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. Journal of veterinary internal medicine, 2020, Volume: 34, Issue:6 Topics: Animals; Dog Diseases; Dogs; Furosemide; Heart Failure; Mitral Valve; Prospective Studies; Pyridazin	2020
Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. Journal of veterinary internal medicine, 2021, Volume: 35, Issue:2 Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; H	2021
Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. Journal of veterinary science, 2018, Jan-31, Volume: 19, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Dog Diseases; Dogs; Drug Combinatio	2018
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. Journal of veterinary internal medicine, 2018, Volume: 32, Issue:1 Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Heart Diseases; Hea	2018
Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease. Journal of veterinary internal medicine, 2018, Volume: 32, Issue:5 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs	2018
Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial. BMC veterinary research, 2019, Jul-09, Volume: 15, Issue:1 Topics: Animals; Biomarkers; Dog Diseases; Dogs; Exercise Test; Female; Heart Valve Diseases; Male; Natriure	2019
Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2015, Volume: 17, Issue:2 Topics: Animals; Arrhythmias, Cardiac; Breeding; Cardiotonic Agents; Dog Diseases; Dogs; Double-Blind Method	2015
Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study. Australian veterinary journal, 2016, Volume: 94, Issue:9 Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Kansas; Lung; Maryland; Mitral Va	2016
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. Journal of veterinary internal medicine, 2016, Volume: 30, Issue:6 Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral V	2016
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. The Journal of small animal practice, 2005, Volume: 46, Issue:3 Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Electrocardiography; Heart Failure; Mitral Valve; M	2005

Article

Year

The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.

BMC veterinary research, 2021, Sep-25, Volume: 17, Issue:1

Topics: Animals; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Method; Heart Valve Diseases; Pyridazi

2021

Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.

Journal of veterinary internal medicine, 2022, Volume: 36, Issue:6

Topics: Animals; Dog Diseases; Dogs; Heart Valve Diseases; Kidney; Mitral Valve; Prospective Studies; Qualit

2022

Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.

PloS one, 2019, Volume: 14, Issue:10

Topics: Animals; Cardiomegaly; Dog Diseases; Dogs; Echocardiography; Exercise Test; Female; Heart Murmurs; H

2019

Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.

Journal of veterinary internal medicine, 2020, Volume: 34, Issue:6

Topics: Animals; Dog Diseases; Dogs; Furosemide; Heart Failure; Mitral Valve; Prospective Studies; Pyridazin

2020

Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.

Journal of veterinary internal medicine, 2021, Volume: 35, Issue:2

Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; H

2021

Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.

Journal of veterinary science, 2018, Jan-31, Volume: 19, Issue:1

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Dog Diseases; Dogs; Drug Combinatio

2018

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.

Journal of veterinary internal medicine, 2018, Volume: 32, Issue:1

Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Heart Diseases; Hea

2018

Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.

Journal of veterinary internal medicine, 2018, Volume: 32, Issue:5

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs

2018

Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.

BMC veterinary research, 2019, Jul-09, Volume: 15, Issue:1

Topics: Animals; Biomarkers; Dog Diseases; Dogs; Exercise Test; Female; Heart Valve Diseases; Male; Natriure

2019

Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2015, Volume: 17, Issue:2

Topics: Animals; Arrhythmias, Cardiac; Breeding; Cardiotonic Agents; Dog Diseases; Dogs; Double-Blind Method

2015

Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.

Australian veterinary journal, 2016, Volume: 94, Issue:9

Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Kansas; Lung; Maryland; Mitral Va

2016

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.

Journal of veterinary internal medicine, 2016, Volume: 30, Issue:6

Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral V

2016

Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.

The Journal of small animal practice, 2005, Volume: 46, Issue:3

Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Electrocardiography; Heart Failure; Mitral Valve; M

2005

Other Studies

28 other studies available for pimobendan and Canine Diseases

Article	Year
Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques. Veterinary research communications, 2022, Volume: 46, Issue:2 Topics: Animals; Dog Diseases; Dogs; Furosemide; Humans; Mitral Valve; Pyridazines; Retrospective Studies; S	2022
Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus). American journal of veterinary research, 2022, Jan-12, Volume: 83, Issue:4 Topics: Administration, Oral; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Half-Life; Male; Pilo	2022
Echocardiographic evaluation of regurgitant fraction in dogs with subclinical myxomatous mitral valve disease: Method comparison, effects of pimobendan, and reproducibility. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2023, Volume: 45 Topics: Animals; Dog Diseases; Dogs; Echocardiography; Heart Valve Diseases; Mitral Valve; Reproducibility o	2023
Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation. BMC veterinary research, 2023, Aug-23, Volume: 19, Issue:1 Topics: Animals; Dog Diseases; Dogs; Hydrogen Peroxide; Mitochondria; Mitral Valve Insufficiency; Muscle Cel	2023
Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs. BMC veterinary research, 2023, Oct-12, Volume: 19, Issue:1 Topics: Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs; Enalapril; Furosemide; Heart Rate; Mitra	2023
Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. Journal of veterinary internal medicine, 2020, Volume: 34, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dog Diseases; Dogs; Electrolytes; Hear	2020
Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease. Open veterinary journal, 2020, Volume: 9, Issue:4 Topics: Animals; Atrial Function, Left; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Valve Diseases	2020
Resolution of caval syndrome during initial hemodynamic stabilization in dogs with heartworm disease. Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001), 2020, Volume: 30, Issue:3 Topics: Animals; Cardiotonic Agents; Dirofilariasis; Dog Diseases; Dogs; Female; Heart Diseases; Hemodynamic	2020
Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2020, Volume: 32 Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Hypertension, Pulmonary; Infusion	2020
Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols. Polish journal of veterinary sciences, 2021, Volume: 24, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cohort Studies; Death; Dog Diseases; Dogs; Female	2021
Clinical and pathological features and outcome of bilateral incidental adrenocortical carcinomas in a dog. The Journal of veterinary medical science, 2017, Sep-12, Volume: 79, Issue:9 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Amlodipine; Animals; Dog Diseases; Dogs; Female;	2017
Clinical trial results extend drug licence. The Veterinary record, 2017, Volume: 181, Issue:18 Topics: Animals; Clinical Trials as Topic; Dog Diseases; Dogs; Legislation, Drug; Mitral Valve Insufficiency	2017
Clinical findings and survival time in dogs with advanced heart failure. Journal of veterinary internal medicine, 2018, Volume: 32, Issue:3 Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val	2018
Effect of sildenafil and pimobendan on intracardiac heartworm infections in four dogs. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2019, Volume: 23 Topics: Animals; Antigens, Helminth; Arsenicals; Dirofilaria; Dirofilariasis; Dog Diseases; Dogs; Female; Fi	2019
Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog. Acta veterinaria Scandinavica, 2016, Jul-07, Volume: 58, Issue:1 Topics: Animals; Antiparasitic Agents; Dog Diseases; Dogs; Doxycycline; Ehrlichiosis; Heart Failure; Hyperte	2016
Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. The Journal of veterinary medical science, 2017, Jan-20, Volume: 79, Issue:1 Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral Valve Insuffici	2017
Treatment of congestive heart failure in dogs. The Veterinary record, 2008, Oct-25, Volume: 163, Issue:17 Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Randomized Controlled T	2008
Canine heart disease: progress and promise. The Journal of small animal practice, 2008, Volume: 49, Issue:11 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Dog Diseases; Dogs; Forecasti	2008
ECG of the month. Arrhythmogenic right ventricular cardiomyopathy in a Boxer. Journal of the American Veterinary Medical Association, 2010, May-01, Volume: 236, Issue:9 Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzazepines; Cardiomyopathies; Cardiotoni	2010
Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases. The Journal of small animal practice, 2010, Volume: 51, Issue:8 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Breeding; Cardiomyopathy, Dilated; Cardiotonic Ag	2010
Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease. The Veterinary record, 2011, Feb-26, Volume: 168, Issue:8 Topics: Animals; Cardiomegaly; Cardiotonic Agents; Clinical Trials as Topic; Dog Diseases; Dogs; Mitral Valv	2011
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. The Canadian veterinary journal = La revue veterinaire canadienne, 2011, Volume: 52, Issue:11 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Death, Sudden,	2011
Transthoracic echocardiographically-guided interventional cardiac procedures in the dog. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2012, Volume: 14, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Balloon Valvuloplasty; Benzazepines; Cardiotonic	2012
Investigation of pimobendan versus benazepril in canine myxomatous valvular disease. The Veterinary record, 2003, Oct-04, Volume: 153, Issue:14 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Clinical Trials	2003
Treatment of congestive heart failure. The Journal of small animal practice, 2003, Volume: 44, Issue:11 Topics: Animals; Cardiotonic Agents; Data Interpretation, Statistical; Dog Diseases; Dogs; Heart Failure; Py	2003
Preclinical dilated cardiomyopathy in the dobermann. The Veterinary record, 2006, May-27, Volume: 158, Issue:21 Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Male; Pyridazines;	2006
A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure. Veterinary research communications, 2007, Volume: 31, Issue:6 Topics: Animals; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Cardiotonic Agents; Dog Disease	2007
Effects of pimobendan for mitral valve regurgitation in dogs. The Journal of veterinary medical science, 2007, Volume: 69, Issue:4 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiotonic Agents; Catecholamines;	2007

Article

Year

Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques.

Veterinary research communications, 2022, Volume: 46, Issue:2

Topics: Animals; Dog Diseases; Dogs; Furosemide; Humans; Mitral Valve; Pyridazines; Retrospective Studies; S

2022

Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus).

American journal of veterinary research, 2022, Jan-12, Volume: 83, Issue:4

Topics: Administration, Oral; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Half-Life; Male; Pilo

2022

Echocardiographic evaluation of regurgitant fraction in dogs with subclinical myxomatous mitral valve disease: Method comparison, effects of pimobendan, and reproducibility.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2023, Volume: 45

Topics: Animals; Dog Diseases; Dogs; Echocardiography; Heart Valve Diseases; Mitral Valve; Reproducibility o

2023

Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation.

BMC veterinary research, 2023, Aug-23, Volume: 19, Issue:1

Topics: Animals; Dog Diseases; Dogs; Hydrogen Peroxide; Mitochondria; Mitral Valve Insufficiency; Muscle Cel

2023

Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.

BMC veterinary research, 2023, Oct-12, Volume: 19, Issue:1

Topics: Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs; Enalapril; Furosemide; Heart Rate; Mitra

2023

Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.

Journal of veterinary internal medicine, 2020, Volume: 34, Issue:1

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dog Diseases; Dogs; Electrolytes; Hear

2020

Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.

Open veterinary journal, 2020, Volume: 9, Issue:4

Topics: Animals; Atrial Function, Left; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Valve Diseases

2020

Resolution of caval syndrome during initial hemodynamic stabilization in dogs with heartworm disease.

Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001), 2020, Volume: 30, Issue:3

Topics: Animals; Cardiotonic Agents; Dirofilariasis; Dog Diseases; Dogs; Female; Heart Diseases; Hemodynamic

2020

Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2020, Volume: 32

Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Hypertension, Pulmonary; Infusion

2020

Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols.

Polish journal of veterinary sciences, 2021, Volume: 24, Issue:1

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cohort Studies; Death; Dog Diseases; Dogs; Female

2021

Clinical and pathological features and outcome of bilateral incidental adrenocortical carcinomas in a dog.

The Journal of veterinary medical science, 2017, Sep-12, Volume: 79, Issue:9

Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Amlodipine; Animals; Dog Diseases; Dogs; Female;

2017

Clinical trial results extend drug licence.

The Veterinary record, 2017, Volume: 181, Issue:18

Topics: Animals; Clinical Trials as Topic; Dog Diseases; Dogs; Legislation, Drug; Mitral Valve Insufficiency

2017

Clinical findings and survival time in dogs with advanced heart failure.

Journal of veterinary internal medicine, 2018, Volume: 32, Issue:3

Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val

2018

Effect of sildenafil and pimobendan on intracardiac heartworm infections in four dogs.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2019, Volume: 23

Topics: Animals; Antigens, Helminth; Arsenicals; Dirofilaria; Dirofilariasis; Dog Diseases; Dogs; Female; Fi

2019

Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog.

Acta veterinaria Scandinavica, 2016, Jul-07, Volume: 58, Issue:1

Topics: Animals; Antiparasitic Agents; Dog Diseases; Dogs; Doxycycline; Ehrlichiosis; Heart Failure; Hyperte

2016

Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.

The Journal of veterinary medical science, 2017, Jan-20, Volume: 79, Issue:1

Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral Valve Insuffici

2017

Treatment of congestive heart failure in dogs.

The Veterinary record, 2008, Oct-25, Volume: 163, Issue:17

Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Randomized Controlled T

2008

Canine heart disease: progress and promise.

The Journal of small animal practice, 2008, Volume: 49, Issue:11

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Dog Diseases; Dogs; Forecasti

2008

ECG of the month. Arrhythmogenic right ventricular cardiomyopathy in a Boxer.

Journal of the American Veterinary Medical Association, 2010, May-01, Volume: 236, Issue:9

Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzazepines; Cardiomyopathies; Cardiotoni

2010

Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases.

The Journal of small animal practice, 2010, Volume: 51, Issue:8

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Breeding; Cardiomyopathy, Dilated; Cardiotonic Ag

2010

Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.

The Veterinary record, 2011, Feb-26, Volume: 168, Issue:8

Topics: Animals; Cardiomegaly; Cardiotonic Agents; Clinical Trials as Topic; Dog Diseases; Dogs; Mitral Valv

2011

Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.

The Canadian veterinary journal = La revue veterinaire canadienne, 2011, Volume: 52, Issue:11

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Death, Sudden,

2011

Transthoracic echocardiographically-guided interventional cardiac procedures in the dog.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2012, Volume: 14, Issue:3

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Balloon Valvuloplasty; Benzazepines; Cardiotonic

2012

Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.

The Veterinary record, 2003, Oct-04, Volume: 153, Issue:14

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Clinical Trials

2003

Treatment of congestive heart failure.

The Journal of small animal practice, 2003, Volume: 44, Issue:11

Topics: Animals; Cardiotonic Agents; Data Interpretation, Statistical; Dog Diseases; Dogs; Heart Failure; Py

2003

Preclinical dilated cardiomyopathy in the dobermann.

The Veterinary record, 2006, May-27, Volume: 158, Issue:21

Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Male; Pyridazines;

2006

A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure.

Veterinary research communications, 2007, Volume: 31, Issue:6

Topics: Animals; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Cardiotonic Agents; Dog Disease

2007

Effects of pimobendan for mitral valve regurgitation in dogs.

The Journal of veterinary medical science, 2007, Volume: 69, Issue:4

Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiotonic Agents; Catecholamines;

2007